Psychedelic prodrug from 200+ fungi species gaining policy and market traction
Eli Lilly has announced an all-cash deal to acquire AtaiBeckley for up to $2.8 billion upfront, plus milestones. AtaiBeckley's lead drug, a DMT-related nasal spray for treatment-resistant depression, is in Phase 3 with results expected in 2029. The deal signals growing momentum for psychedelic therapies amid regulatory support.
This week has seen several medical research and regulatory developments. Insilico Medicine has reported that its experimental drug rentosertib changed blood‑protein patterns that aging clocks read as three to four years younger in a small trial. Stanford teams have published studies showing they can grow hindbrain neurons separately and implant human cortical organoids into mice. The US health department has appointed permanent directors for three FDA centers.